GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
TAK-733 Sensitive: D – Preclinical
|
TAK-733 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
enzastaurin Sensitive: D – Preclinical
|
enzastaurin Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
AEB071 Sensitive: D – Preclinical
|
AEB071 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
U0126 Sensitive: D – Preclinical
|
U0126 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
FR900359 Sensitive: D – Preclinical
|
FR900359 Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
GNAQ Q209L
|
Uveal Melanoma
|
GNAQ Q209L
|
Uveal Melanoma
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
MEK inhibitor + YM-254890 Sensitive: D – Preclinical
|
